{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:50:30Z","timestamp":1791355830428,"version":"4.3.1"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Gemcitabine (GEM) resistance limits treatment efficacy in bladder cancer (BC). This study identified MAN1B1 as a key driving factor for chemotherapy resistance and malignant progression in BC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Bulk-RNA datasets GSE190636 and single-cell RNA-seq dataset GSE250523 from GEO. Use limma package to identify differentially expressed genes (DEGs) in the process of GEM resistance, and then perform GO and KEGG enrichment analysis. Screening candidate targets through molecular docking with GEM, and further evaluation through molecular dynamics simulation and GEPIA survival analysis. GSEA analysis is used to explore pathways associated with key genes. Perform single-cell analysis using Seurat, SingleR, Monocle 2, CellChat, and scTenifoldKnk, including cell annotation, pseudo time trajectory, intercellular communication, and virtual knockout. Carry out functional experiments in bladder cancer cell lines, including cell viability, wound healing Transwell, Colony formation and Western blot analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Through comprehensive transcriptome analysis and single-cell sequencing, we found that elevated levels of MAN1B1 are associated with poorer clinical outcomes. Computational molecular docking and molecular dynamics simulations indicate the potential binding interaction between MAN1B1 and GEM.This enzyme orchestrates a dual microenvironmental reprogramming by hyperactivating metabolic cascades while simultaneously dampening anti-tumor immune surveillance, predominantly originating from the epithelial compartment to modulate intercellular crosstalk. Functional disturbance experiments showed that knockout of MAN1B1 was associated with decreased cell survival, migration, and invasion, as well as increased sensitivity to GEM, while ectopic expression of MAN1B1 increased cell survival and was associated with enhanced PI3K\/AKT\/mTOR pathway activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings uncover the multifaceted regulatory network governing MAN1B1, establishing its utility as an innovative prognostic indicator and an actionable therapeutic vulnerability for overcoming GEM insensitivity in urological oncology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1958628","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:58:40Z","timestamp":1791352720000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrated analyses identify MAN1B1 as a candidate regulator of chemotherapeutic tolerance and immunosuppression in bladder cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Mingzhe","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Oncology, General Hospital of Northern Theater Command","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Oncology, General Hospital of Northern Theater Command","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, General Hospital of Northern Theater Command","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dantong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Oncology, General Hospital of Northern Theater Command","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, General Hospital of Northern Theater Command","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhendong","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Oncology, General Hospital of Northern Theater Command","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.eururo.2024.12.002","article-title":"The financial burden of localized and metastatic bladder cancer","volume":"87","author":"Scilipoti","year":"2024","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2024.01.006","article-title":"Cancer incidence and mortality in China, 2022","volume":"46","author":"Zheng","year":"2024","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"B4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s40779-024-00569-w","article-title":"Global burden of benign prostatic hyperplasia, urinary tract infections, urolithiasis, bladder cancer, kidney cancer, and prostate cancer from 1990 to 2021","volume":"11","author":"Zi","year":"2024","journal-title":"Mil Med Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1038\/551s34a","article-title":"Unlocking bladder cancer","volume":"551","author":"Berdik","year":"2017","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1038\/551s33a","article-title":"Bladder cancer","volume":"551","author":"Grayson","year":"2017","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: A review","volume":"324","author":"Lenis","year":"2020","journal-title":"Jama"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0011","article-title":"Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Flaig","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"B13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01188-6","article-title":"Current best practice for bladder cancer: a narrative review of diagnostics and treatments","volume":"400","author":"Comp\u00e9rat","year":"2022","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41571-018-0026-y","article-title":"Treatment resistance in urothelial carcinoma: an evolutionary perspective","volume":"15","author":"Vlachostergios","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1997.15.12.3441","article-title":"Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer","volume":"15","author":"Moore","year":"1997","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.07.083","article-title":"Synergistic antitumour effects of triptolide plus gemcitabine in bladder cancer","volume":"106","author":"Yang","year":"2018","journal-title":"BioMed Pharmacother"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.12.090","article-title":"Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: A systematic review and meta-analysis","volume":"197","author":"Chou","year":"2017","journal-title":"J Urol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.12.9791","article-title":"How to build and interpret a nomogram for cancer prognosis","volume":"26","author":"Iasonos","year":"2008","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.65.5654","article-title":"Assessing the clinical impact of risk prediction models with decision curves: guidance for correct interpretation and appropriate use","volume":"34","author":"Kerr","year":"2016","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj966","article-title":"Actual experience and future development of gemcitabine in superficial bladder cancer","volume":"17","author":"Gontero","year":"2006","journal-title":"Ann Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.eururo.2012.08.010","article-title":"ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings","volume":"63","author":"Sternberg","year":"2013","journal-title":"Eur Urol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/ncb3038","article-title":"Bladder cancers arise from distinct urothelial sub-populations","volume":"16","author":"Van Batavia","year":"2014","journal-title":"Nat Cell Biol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4111\/icu.20210265","article-title":"Intravesical gemcitabine for non-muscle invasive bladder cancer","volume":"6","author":"Han","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"B25","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.eururo.2009.06.010","article-title":"Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study","volume":"56","author":"B\u00f6hle","year":"2009","journal-title":"Eur Urol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.02763","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"41","author":"von der Maase","year":"2023","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3390\/genes13030466","article-title":"Recent development of prodrugs of gemcitabine","volume":"13","author":"Pandit","year":"2022","journal-title":"Genes (Basel)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-00313-1","article-title":"Advances in bladder cancer biology and therapy","volume":"21","author":"Tran","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.4656","article-title":"Simplifying treatment and reducing recurrence for patients with early-stage bladder cancer","volume":"319","author":"Kaffenberger","year":"2018","journal-title":"Jama"},{"key":"B30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/upj.0000000000000481","article-title":"US clinical practice patterns of intravesical chemotherapy for bacillus calmette-gu\u00e9rin-unresponsive and bacillus calmette-gu\u00e9rin-exposed nonmuscle-invasive bladder cancer","volume":"11","author":"Abou Chakra","year":"2024","journal-title":"Urol Pract"},{"key":"B31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.euros.2024.01.013","article-title":"The safety, tolerability, and preliminary efficacy of a gemcitabine-releasing intravesical system (TAR-200) in American urological association-defined intermediate-risk non-muscle-invasive bladder cancer patients: A phase 1b study","volume":"62","author":"FJ","year":"2024","journal-title":"Eur Urol Open Sci"},{"key":"B32","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1097\/ju.0000000000003195","article-title":"Safety, tolerability, and preliminary efficacy of TAR-200 in patients with muscle-invasive bladder cancer who refused or were unfit for curative-intent therapy: A phase 1 study","volume":"209","author":"Tyson","year":"2023","journal-title":"J Urol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16208","article-title":"Alternative instillation techniques of sequential intravesical gemcitabine and docetaxel for non-muscle-invasive bladder cancer","volume":"133","author":"McElree","year":"2024","journal-title":"BJU Int"},{"key":"B34","doi-asserted-by":"publisher","first-page":"33","DOI":"10.5489\/cuaj.8341","article-title":"Salvage therapy for BCG failure with intravesical sequential gemcitabine and docetaxel in patients with recurrent NMIBC","volume":"18","author":"Garneau","year":"2024","journal-title":"Can Urol Assoc J"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.0849","article-title":"Comparison of sequential intravesical gemcitabine and docetaxel vs bacillus calmette-gu\u00e9rin for the treatment of patients with high-risk non-muscle-invasive bladder cancer","volume":"6","author":"McElree","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2019.02.003","article-title":"Polytherapy and targeted cancer drug resistance","volume":"5","author":"Chatterjee","year":"2019","journal-title":"Trends Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-020-0304-1","article-title":"Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes","volume":"17","author":"Meeks","year":"2020","journal-title":"Nat Rev Urol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605912","article-title":"How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine","volume":"103","author":"Gerlinger","year":"2010","journal-title":"Br J Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505917","article-title":"Comprehensive molecular characterization of papillary renal-cell carcinoma","volume":"374","author":"Linehan","year":"2016","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24112","article-title":"Targeting loss of the Hippo signaling pathway in NF2-deficient papillary kidney cancers","volume":"9","author":"Sourbier","year":"2018","journal-title":"Oncotarget"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2019.08.010","article-title":"YAP promotes VEGFA expression and tumor angiogenesis though gli2 in human renal cell carcinoma","volume":"50","author":"Xu","year":"2019","journal-title":"Arch Med Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3892\/or.2014.3349","article-title":"YAP is overexpressed in clear cell renal cell carcinoma and its knockdown reduces cell proliferation and induces cell cycle arrest and apoptosis","volume":"32","author":"Cao","year":"2014","journal-title":"Oncol Rep"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.02767","article-title":"Prognostic factors in high-grade osteosarcoma of theExtremities or trunk: an analysis of 1,702 patients treatedon neoadjuvant cooperative osteosarcoma study groupProtocols","volume":"41","author":"Bielack","year":"2023","journal-title":"J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40880-016-0109-z","article-title":"Hippo\/YAP signaling pathway is involved in osteosarcoma chemoresistance","volume":"35","author":"Wang","year":"2016","journal-title":"Chin J Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"160","DOI":"10.21037\/atm.2018.05.02","article-title":"Emerging application of genomics-guided therapeutics in personalized lung cancer treatment","volume":"6","author":"Zaman","year":"2018","journal-title":"Ann Transl Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/s41419-023-06076-5","article-title":"HLF promotes ovarian cancer progression and chemoresistance via regulating Hippo signaling pathway","volume":"14","author":"Han","year":"2023","journal-title":"Cell Death Dis"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2018.6322","article-title":"Yes-associated protein 1 promotes the metastasis of U251 glioma cells by upregulating Jagged-1 expression and activating the Notch signal pathway","volume":"16","author":"Hao","year":"2018","journal-title":"Exp Ther Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.mcr-19-0375","article-title":"The emerging role of YAP\/TAZ in tumor immunity","volume":"17","author":"Pan","year":"2019","journal-title":"Mol Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/s41416-022-02115-8","article-title":"Hepatitis B virus X protein promotes MAN1B1 expression by enhancing stability of GRP78 via TRIM25 to facilitate hepatocarcinogenesis","volume":"128","author":"You","year":"2023","journal-title":"Br J Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0072829","article-title":"ERManI is a target of miR-125b and promotes transformation phenotypes in hepatocellular carcinoma (HCC)","volume":"8","author":"Pan","year":"2013","journal-title":"PloS One"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1532306","article-title":"Cancer-associated fibroblasts gene signature: a novel approach to survival prediction and immunotherapy guidance in colon cancer","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.70040","article-title":"Targeting MAN1B1 potently enhances bladder cancer antitumor immunity via deglycosylation of CD47","volume":"45","author":"Zhang","year":"2025","journal-title":"Cancer Commun (Lond)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B54","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","article-title":"The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism","volume":"20","author":"Hoxhaj","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B55","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.3390\/ijms21093285","article-title":"Targeting AKT\/mTOR in oral cancer: mechanisms and advances in clinical trials","volume":"21","author":"Harsha","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-15-0140","article-title":"Nicotine induces tumor growth and chemoresistance through activation of the PI3K\/Akt\/mTOR pathway in bladder cancer","volume":"14","author":"Yuge","year":"2015","journal-title":"Mol Cancer Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1958628\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:58:40Z","timestamp":1791352720000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1958628\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":56,"alternative-id":["10.3389\/fimmu.2026.1958628"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1958628","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"1958628"}}